Potent inhibition of feline coronaviruses with peptidyl compounds targeting coronavirus 3C-like protease

Antiviral Research

Volumn 97, Issue 2, 2013, Pages 161-168

  Kim, Yunjeong ^a   Mandadapu, Sivakoteswara Rao ^b   Groutas, William C ^b   Chang, Kyeong Ok ^a  

^a KANSAS STATE UNIVERSITY   (United States)

^b WICHITA STATE UNIVERSITY   (United States)

Author keywords

3CL protease; Cathepsin B; Feline coronaviruses; Feline infectious peritonitis virus; Protease inhibitor; Synergy

Indexed keywords

CATHEPSIN B; CATHEPSIN B INHIBITOR; CORANAVIRUS 3C LIKE PROTEASE; PROTEINASE; UNCLASSIFIED DRUG; VIRUS ENZYME;

ANTIVIRAL ACTIVITY; ARTERIVIRUS; ARTICLE; CAUSE OF DEATH; COMPETITIVE INHIBITION; CORONAVIRUS; DRUG CYTOTOXICITY; ENZYME ACTIVITY; NONHUMAN; PRIORITY JOURNAL; PROTEINASE INHIBITION; VIRUS REPLICATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIVIRAL AGENTS; CATHEPSIN B; CATS; CELL LINE; CORONAVIRUS, FELINE; CYSTEINE ENDOPEPTIDASES; DRUG SYNERGISM; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; PEPTIDES; PROTEASE INHIBITORS; VIRAL PROTEINS; VIRUS REPLICATION;

CORONAVIRUS; FELIDAE; FELINE CORONAVIRUS; FELINE INFECTIOUS PERITONITIS VIRUS;

EID: 84871971468     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2012.11.005     Document Type: Article

References (47)

1. Anand K., Palm G.J., Mesters J.R., Siddell S.G., Ziebuhr J., Hilgenfeld R. Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra alpha-helical domain. EMBO J. 2002, 21:3213-3224.
2. Barlough J.E., Shacklett B.L. Antiviral studies of feline infectious peritonitis virus in vitro. Vet. Rec. 1994, 135:177-179.
3. Benetka V., Kubber-Heiss A., Kolodziejek J., Nowotny N., Hofmann-Parisot M., Mostl K. Prevalence of feline coronavirus types I and II in cats with histopathologically verified feline infectious peritonitis. Vet. Microbiol. 2004, 99:31-42.
4. Chang H.W., de Groot R.J., Egberink H.F., Rottier J.M. Feline infectious peritonitis: insights into feline coronavirus pathobiogenesis and epidemiology based on genetic analysis of the viral 3c gene. J. Gen. Virology 2010, 91:415-420.
5. Chang H.W., Egberink H.F., Rottier P.J. Sequence analysis of feline coronaviruses and the circulating virulent/avirulent theory. Emerg. Infect. Dis. 2011, 17:744-746.
6. Chang H.W., Egberink H.F., Halpin R., Spiro D.J., Rottier P.J. Spike protein fusion peptide and feline coronavirus virulence. Emerg. Infect. Dis. 2012, 18:1089-1095.
7. Chang K.O., Takahashi D., Prakash O., Kim Y. Characterization and inhibition of norovirus proteases of genogroups I and II using a fluorescence resonance energy transfer assay. Virology 2012, 423:125-133.
8. Copeland R.A. Evaluation of Enzyme Inhibitors in Drug Discovery: a Guide for Medicinal Chemists and Pharmacologists (Methods of Biochemical Analysis) 2005, Wiley-Interscience. first ed.
9. Cuerrier D., Moldoveanu T., Davies P.L. Determination of peptide substrate specificity for mu-calpain by a peptide library-based approach: the importance of primed side interactions. J. Biol. Chem. 2005, 280:40632-40641.
10. Fischer Y., Ritz S., Weber K., Sauter-Louis C., Hartmann K. Randomized, placebo controlled study of the effect of propentofylline on survival time and quality of life of cats with feline infectious peritonitis. J. Vet. Intern. Med. 2011, 25:1270-1276.
11. Hartmann K., Ritz S. Treatment of cats with feline infectious peritonitis. Vet. Immunol. Immunopathol. 2008, 123:172-175.
12. Heeney J.L., Evermann J.F., McKeirnan A.J., Marker-Kraus L., Roelke M.E., Bush M., Wildt D.E., Meltzer D.G., Colly L., Lukas J., et al. Prevalence and implications of feline coronavirus infections of captive and free-ranging cheetahs (Acinonyx jubatus). J. Virol. 1990, 64:1964-1972.
13. Hegyi A., Ziebuhr J. Conservation of substrate specificities among coronavirus main proteases. J. Gen. Virol. 2002, 83:595-599.
14. Hegyi A., Friebe A., Gorbalenya A.E., Ziebuhr J. Mutational analysis of the active centre of coronavirus 3C-like proteases. J. Gen. Virol. 2002, 83:581-593.
15. Herrewegh A.A., Vennema H., Horzinek M.C., Rottier P.J., de Groot R.J. The molecular genetics of feline coronaviruses: comparative sequence analysis of the ORF7a/7b transcription unit of different biotypes. Virology 1995, 212:622-631.
16. Herrewegh A.A., Smeenk I., Horzinek M.C., Rottier P.J., de Groot R.J. Feline coronavirus type II strains 79-1683 and 79-1146 originate from a double recombination between feline coronavirus type I and canine coronavirus. J. Virol. 1998, 72:4508-4514.
17. Homes K.V. Coronaviruses. Fields Virology 2001, 1187-1203. Lippincott Williams & Wilkins, Philadelphia. third ed. D.M. Knipe, P.M. Howley (Eds.).
18. Hsieh L.E., Lin C.N., Su B.L., Jan T.R., Chen C.M., Wang C.H., Lin D.S., Lin C.T., Chueh L.L. Synergistic antiviral effect of Galanthus nivalis agglutinin and nelfinavir against feline coronavirus. Antiviral Res. 2010, 88:25-30.
19. Ishida T., Shibanai A., Tanaka S., Uchida K., Mochizuki M. Use of recombinant feline interferon and glucocorticoid in the treatment of feline infectious peritonitis. J. Feline Med. Surg. 2004, 6:107-109.
20. Jaulent A.M., Fahy A.S., Knox S.R., Birtley J.R., Roque-Rosell N., Curry S., Leatherbarrow R.J. A continuous assay for foot-and-mouth disease virus 3C protease activity. Anal. Biochem. 2007, 368:130-137.
21. Kennedy M., Citino S., McNabb A.H., Moffatt A.S., Gertz K., Kania S. Detection of feline coronavirus in captive Felidae in the USA. J. Vet. Diagn. Invest. 2002, 14:520-522.
22. Kim Y., Lovell S., Tiew K., Mandadapu S.R., Alliston K.R., Battaile K.P., Groutas W.C., Chang K.O. Broad-Spectrum Antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses and coronaviruses. J. Virol. 2012, 86:11754-11762.
23. Kummrow M., Meli M.L., Haessig M., Goenczi E., Poland A., Pedersen N.C., Hofmann-Lehmann R., Lutz H. Feline coronavirus serotypes 1 and 2: seroprevalence and association with disease in Switzerland. Clin. Diagn. Lab. Immunol. 2005, 12:1209-1215.
24. Kuo C.J., Chi Y.H., Hsu J.T., Liang P.H. Characterization of SARS main protease and inhibitor assay using a fluorogenic substrate. Biochem. Biophys. Res. Commun. 2004, 318:862-867.
25. Legendre A.M., Bartges J.W. Effect of polyprenyl immunostimulant on the survival times of three cats with the dry form of feline infectious peritonitis. J. Feline Med. Surg. 2009, 11:624-626.
26. Motokawa K., Hohdatsu T., Hashimoto H., Koyama H. Comparison of the amino acid sequence and phylogenetic analysis of the peplomer, integral membrane and nucleocapsid proteins of feline, canine and porcine coronaviruses. Microbiol. Immunol. 1996, 40:425-433.
27. Pedersen N.C. A review of feline infectious peritonitis virus infection: 1963-2008. J. Feline Med. Surg. 2009, 11:225-258.
28. Pedersen N.C., Black J.W., Boyle J.F., Evermann J.F., McKeirnan A.J., Ott R.L. Pathogenic differences between various feline coronavirus isolates. Adv. Exp. Med. Biol. 1984, 173:365-380.
29. Pedersen N.C., Evermann J.F., McKeirnan A.J., Ott R.L. Pathogenicity studies of feline coronavirus isolates 79-1146 and 79-1683. Am. J. Vet. Res. 1984, 45:2580-2585.
30. Pedersen N.C., Allen C.E., Lyons L.A. Pathogenesis of feline enteric coronavirus infection. J. Feline Med. Surg. 2008, 10:529-541.
31. Pedersen N.C., Liu H., Scarlett J., Leutenegger C.M., Golovko L., Kennedy H., Kamal F.M. Feline infectious peritonitis: role of the feline coronavirus 3c gene in intestinal tropism and pathogenicity based upon isolates from resident and adopted shelter cats. Virus Res. 2012, 165:17-28.
32. Poland A.M., Vennema H., Foley J.E., Pedersen N.C. Two related strains of feline infectious peritonitis virus isolated from immunocompromised cats infected with a feline enteric coronavirus. J. Clin. Microbiol. 1996, 34:3180-3184.
33. Prichard M.N., Shipman C. A three-dimensional model to analyze drug-drug interactions. Antiviral Res. 1990, 14:181-205.
34. Qiu Z., Hingley S.T., Simmons G., Yu C., Das Sarma J., Bates P., Weiss S.R. Endosomal proteolysis by cathepsins is necessary for murine coronavirus mouse hepatitis virus type 2 spike-mediated entry. J. Virol. 2006, 80:5768-5776.
35. Reed L.J., Muench H. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 1938, 27:493-497.
36. Regan A.D., Shraybman R., Cohen R.D., Whittaker G.R. Differential role for low pH and cathepsin-mediated cleavage of the viral spike protein during entry of serotype II feline coronaviruses. Vet. Microbiol. 2008, 132:235-248.
37. Ritz S., Egberink H., Hartmann K. Effect of feline interferon-omega on the survival time and quality of life of cats with feline infectious peritonitis. J. Vet. Intern. Med. 2007, 21:1193-1197.
38. Schechter I., Berger A. On the size of the active site in proteases. I. Papain. Biochem. Biophys. Res. Commun. 1967, 27:157-162.
39. Simmons G., Gosalia D.N., Rennekamp A.J., Reeves J.D., Diamond S.L., Bates P. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc. Natl. Acad. Sci. USA 2005, 102:11876-11881.
40. Takahashi D., Kim Y., Chang K.O., Anbanandam A., Prakash O. Backbone and side-chain (1)H, (15)N, and (13)C resonance assignments of Norwalk virus protease. Biomol. NMR Assign. 2012, 85:12570-12577.
41. Tiew K.C., He G., Aravapalli S., Mandadapu S.R., Gunnam M.R., Alliston K.R., Lushington G.H., Kim Y., Chang K.O., Groutas W.C. Design, synthesis, and evaluation of inhibitors of Norwalk virus 3C protease. Bioorg. Med. Chem. Lett. 2011, 21:5315-5319.
42. Vennema H., Poland A., Foley J., Pedersen N.C. Feline infectious peritonitis viruses arise by mutation from endemic feline enteric coronaviruses. Virology 1998, 243:150-157.
43. Vogel L., Van der Lubben M., te Lintelo E.G., Bekker C.P., Geerts T., Schuijff L.S., Grinwis G.C., Egberink H.F., Rottier P.J. Pathogenic characteristics of persistent feline enteric coronavirus infection in cats. Vet. Res. 2010, 41:71.
44. Weiss R.C., Cox N.R., Martinez M.L. Evaluation of free or liposome-encapsulated ribavirin for antiviral therapy of experimentally induced feline infectious peritonitis. Res. Vet. Sci. 1993, 55:162-172.
45. Xie H., Lin L., Tong L., Jiang Y., Zheng M., Chen Z., Jiang X., Zhang X., Ren X., Qu W., Yang Y., Wan H., Chen Y., Zuo J., Jiang H., Geng M., Ding J. AST1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo. PLoS One 2011, 6:e21487.
46. Yang H., Xie W., Xue X., Yang K., Ma J., Liang W., Zhao Q., Zhou Z., Pei D., Ziebuhr J., Hilgenfeld R., Yuen K.Y., Wong L., Gao G., Chen S., Chen Z., Ma D., Bartlam M., Rao Z. Design of wide-spectrum inhibitors targeting coronavirus main proteases. PLoS Biol. 2005, 3:e324.
47. Ziebuhr J., Snijder E.J., Gorbalenya A.E. Virus-encoded proteinases and proteolytic processing in the Nidovirales. J. Gen. Virol. 2000, 81:853-879.